Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

26.94 USD +0.48 (+1.81%)
Streaming Delayed Price Updated: 6:07 AM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aclaris Therapts

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
From GlobeNewswire News Releases
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
From GlobeNewswire News Releases
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private... 
From Business Wire News Releases
Aclaris Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Aclaris Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
From GlobeNewswire News Releases
Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?
InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV. 
From PR Newswire
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
From GlobeNewswire News Releases
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
From GlobeNewswire News Releases
Silverback Therapeutics Expands Executive Team With Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer
Silverback Therapeutics Expands Executive Team with Appointment of Healthcare Investment Banking Veteran Jonathan Piazza as Chief Financial Officer 
From Business Wire News Releases
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
From GlobeNewswire News Releases
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatiti
From GlobeNewswire News Releases
Aclaris Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
From GlobeNewswire News Releases
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
From GlobeNewswire News Releases
Thinking about buying stock in Biocept, TOP Ships, Aclaris Therapeutics, Seanergy Maritime, or InnerWorkings?
InvestorsObserver issues critical PriceWatch Alerts for BIOC, TOPS, ACRS, SHIP, and INWK. 
From PR Newswire
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
From GlobeNewswire News Releases
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
From GlobeNewswire News Releases
Aclaris Therapeutics Secures $11 Million Term Loan Facility
From GlobeNewswire News Releases
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
From GlobeNewswire News Releases
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
From GlobeNewswire News Releases
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
From GlobeNewswire News Releases
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
From GlobeNewswire News Releases
NASDAQ: ACRS Long Term Investor Alert: Investigation of Potential Wrongdoing at Aclaris Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 12/12/2019 -- An investigation on behalf of current long term investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares over possible breaches of fiduciary duty by... 
From SBWire - Latest Press Releases
Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)
Shareholder rights law firm Robbins LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a derivative complaint against the company's officers and directors for breaches of... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.